{
    "clinical_study": {
        "@rank": "11820", 
        "brief_summary": {
            "textblock": "OBJECTIVES: I.   Determine the effect of intravenous immunoglobulin on recovery time of\n      patients with proximal diabetic neuropathy.\n\n      II.  Determine whether rate of response is dose dependent in these patients."
        }, 
        "brief_title": "Randomized Study of Intravenous Immunoglobulin (IVIg) in Patients With Subacute Proximal Diabetic Neuropathy", 
        "condition": "Diabetic Neuropathies", 
        "condition_browse": {
            "mesh_term": "Diabetic Neuropathies"
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled study.  Patients\n      are randomized to treatment with low dose intravenous immunoglobulin (IVIg), high dose IVIg,\n      or placebo.\n\n      Patients must first complete baseline evaluation.  Patients receive IVIg or placebo on days\n      1, 2, 3, and 5, biweekly at weeks 2-4, weekly at weeks 5-8, and every other week at weeks\n      9-12.\n\n      Patients are assessed at 6, 12, 36, 52, and 104 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics--\n\n          -  Diagnostically proven non-insulin dependent diabetes mellitus as defined by the\n             following criteria: Presence of classic symptoms, such as polyuria, polydipsia,\n             ketonuria, and rapid weight loss, together with plasma glucose elevations Elevated\n             fasting glucose concentration on more than one occasion\n\n          -  Diagnostically proven proximal diabetic neuropathy with any of the following\n             symptoms: Severe thigh, hip, or leg pain Greater than 20% weight loss Progressive\n             proximal weakness in the painful leg Weakness in the contralateral lower limb\n             Thoracic or cervical root distribution Symmetric distal polyneuropathy or autonomic\n             neuropathy may be mild or absent\n\n        --Prior/Concurrent Therapy--\n\n          -  At least 6 months since prior immunosuppression or plasma exchange\n\n          -  No history of prior renal transplant\n\n        --Patient Characteristics--\n\n          -  Age: 18 and over\n\n          -  Performance status: Gait impairment at least grade 2\n\n          -  Hematopoietic: Not specified\n\n          -  Hepatic: Not specified\n\n          -  Renal: Creatinine no greater than 1.4 mg/dL (women) Creatinine no greater than 1.5\n             mg/dL (men) No history of renal failure\n\n          -  Cardiovascular: No history of cardiac failure\n\n          -  Neurologic: Normal nerve conduction studies or changes compatible with distal\n             symmetric diabetic neuropathy or diabetic lumbosacral radioplexus neuropathy Spinal\n             fluid cell count less than 5 cells/mm3 Normal cerebral spinal fluid cytology No\n             structural spine disease No inherited neuropathy\n\n          -  Other: Electromyographic evidence of proximal lower limb plexus OR Radicular\n             denervation compatible with proximal diabetic neuropathy No other systemic disease or\n             malignancy Normal IgA levels No chronic inflammatory demyelinating\n             polyradiculoneuropathy (CIDP) No systemic amyloidosis No monoclonal gammopathy\n             associated neuropathy No history of allergy to serum products No selective cervical\n             or root involvement without lower limb weakness No evidence of secondary diabetes"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "75", 
        "firstreceived_date": "October 18, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004407", 
            "org_study_id": "199/13294", 
            "secondary_id": [
                "MAYOC-91596", 
                "MAYOC-FDR001358"
            ]
        }, 
        "intervention": {
            "intervention_name": "immune globulin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Immunoglobulins", 
                "Immunoglobulins, Intravenous", 
                "Rho(D) Immune Globulin"
            ]
        }, 
        "keyword": [
            "diabetic amyotrophy", 
            "diabetic lumbosacral radiculoplexus neuropathy", 
            "diabetic neuropathy", 
            "diabetic proximal neuropathy", 
            "neurologic and psychiatric disorders", 
            "rare disease"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "Anthony J. Windebank", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004407"
        }, 
        "source": "FDA Office of Orphan Products Development", 
        "sponsors": {
            "collaborator": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "FDA Office of Orphan Products Development", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "February 1998", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2001"
    }, 
    "geocoordinates": {}
}